Disingenous Remarks from AMA President on Tort Reform – letter BMJ / NYT Test a Lawyer’s Ingenuity

Disingenous Remarks from AMA President on Tort Reform – letter BMJ / NYT Test a Lawyer’s Ingenuity Sun, 6 Mar 2005 Responding to an article in the BMJ about President Bush’s bill to restrict class action suits for medical malpractice-http://bmj.bmjjournals.com/cgi/content/full/330/7490/499-c – the president of the American Medical Association, Dr. John…

Spitzer Expands drug Probe: Johnson & Johnson / New FDA analysis Confirms SSRI Risks to Kids – WSJ

Spitzer Expands drug Probe: Johnson & Johnson / New FDA analysis Confirms SSRI Risks to Kids – WSJ Thu, 5 Aug 2004 A front page article in The Wall Street Journal reports that a second FDA analysis of 25 clinical trials of SSRI antidepressants in children was conducted after a…

GlascoSmithKline PAXIL Warning letter to Healthcare Professionals

GlascoSmithKline PAXIL Warning letter to Healthcare Professionals Thu, 19 Jun 2003 On June 10 the British government disapproved a license the widely popular, SSRI antidepressant, Seroxat (PAXIL), for use in children and adolescents after a committee examined the data from 9 clinical trials. The British Medicine and Healthcare Products Regulatory…

Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data

Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data Tue, 3 Aug 2004 A hearing about the possible connection between suicide and antidepressant drugs will be held on Aug 4, by the California Senate by Sen. Tom Torkalson, chairman of the Senate Task Force on Youth and Workplace Wellness…

BBC Panorama: Unprecedented public response to evidence of SSRI drug harm

BBC Panorama: Unprecedented public response to evidence of SSRI drug harm Wed, 21 May 2003 In a stunning follow up to its investigative report, The Secret of Seroxat, aired October 13, 2002, the British Broadcasting Company (BBC) featured the public responses to its earlier program as the focus of its…

FDA New Drug Safety Website – ADHD A Huge Profit-Engine for amphetamine-like drugs – The Street

FDA New Drug Safety Website – ADHD A Huge Profit-Engine for amphetamine-like drugs – The Street Sun, 22 May 2005 “After 25 years and 35 studies, there is not a single straightforward experiment comparing typical unmedicated children with an ADHD diagnosis to typical controls.” But science is not what the…

Intimidation, Politics and Drug Industry Cripple U.S. Medicine – FDA Permits Dr. David Graham to publish Vioxx Report

Intimidation, Politics and Drug Industry Cripple U.S. Medicine – FDA Permits Dr. David Graham to publish Vioxx Report Wed, 5 Jan 2005 FDA officials could not maintain their iron grip in an effort to suppress evidence of far reaching lethal effects of Vioxx when their actions were in full public…

Unreported Paxil suicides: company abandons "No Addiction" claim

Unreported Paxil suicides: company abandons “No Addiction” claim Sat, 10 May 2003 GlaxoSmithKline, Britain’s biggest pharmaceutical company will change the label in the UK to reflect the severe withdrawal that its antidepressant drug, Seroxat (Paxil in US) generates in many patients. In Britain, the package label will no longer claim…

Prozac Suicide Risk – CNN Posts long concealed Eli Lilly Internal Documents

Prozac Suicide Risk – CNN Posts long concealed Eli Lilly Internal Documents Tue, 4 Jan 2005 An internal company document titled Activation and Sedation in Fluoxetine Clinical Trials dated 11/8/1988, provides insight into how marketing divisions of pharmaceutical companies rationalize lethal adverse drug effects. Of note: the terminology in 1988…

Hoffman LaRoche Rebuffed Call to Monitor Accutane Users – USA Today

Hoffman LaRoche Rebuffed Call to Monitor Accutane Users – USA Today Tue, 7 Dec 2004 An investigative cover story in USA Today – Drugmaker Rebuffed Call to Monitor Users–affirms the indispensable role of litigation in bringing the facts about adverse drug effects to public knowledge. Lawsuits against Hoffman-La Roche, manufacturer…

Dr. David Healy Addresses Credibility Crisis-at Columbia University Oct. 20

Additional information as of late Wed Oct 19: Although I was assured that attendance for a presentation by Dr. David Healy (at Columbia University School of Public Health on Oct. 20 at 12:30) would be open to the public, a problem seems to have emerged after an AHRP Infomail about…